Key result
Anticoagulant and antiplatelet therapies may paradoxically increase thrombotic risk and cancer progression by driving plasmin-dependent activation of cancer-derived TGF-β, suggesting a potential benefit for combined anti-TGF-β therapy.
Why the study?
Molecular mechanisms of cancer-associated thrombosis are not fully elucidated, and recurrent events and mortality remain high despite anticoagulant or antiplatelet therapy.
Answers are grounded in this paper and cite their sources.
The review hypothesizes that anticoagulant/antiplatelet therapy in cancer patients may paradoxically drive cancer-associated thrombosis and tumor progression via plasmin-dependent TGF-β activation, suggesting a potential role for adjunctive anti-TGF-β therapy.
While the prevalence of cancer-associated thrombosis (CAT) is high in cancer patients, its molecular mechanisms have not been fully elucidated. Moreover, the risks of recurrent CAT events and mortality remain high in cancer patients despite the introduction of anticoagulant/antiplatelet therapy. Here, we discuss the possibility that increased plasmin activity driven by anticoagulant/antiplatelet treatment might be the major mechanism responsible for the activation of an excess of cancer-derived transforming growth factor-beta (TGF-β) originating from cancer cells and the tumour microenvironment. Hence, high coagulation and fibrinolysis rates in cancer patients may be linked to high rates of TGF-β activation, especially the excess of TGF-β derived from cancer cells. In turn, high TGF-β activation could contribute directly to maintaining high thrombotic risk and CAT recurrence in cancer patients since TGF-β signalling increases gene expression and secretion of the fibrinolysis inhibitor plasminogen activator inhibitor 1 (PAI1). Thus, TGF-β could directly contribute to the high number of deaths among patients with cancer experiencing CAT, despite anticoagulant/antiplatelet treatment. In a longer-term perspective, increased TGF-β activation, by supporting a pro-coagulant cancer microenvironment, might also accelerate cancer progression. This review aims to discuss the published evidence that might support the scenario described above, and to put forward the hypothesis that cancer patients experiencing CAT events would largely benefit from anti-TGF-β therapy.
No takes yet. Share an insight, caveat, or question.
Smęda et al. (2024) conducted a review in Cancer-associated thrombosis. Anticoagulant and antiplatelet therapy was evaluated. Anticoagulant and antiplatelet therapies may paradoxically increase thrombotic risk and cancer progression by driving plasmin-dependent activation of cancer-derived TGF-β, suggesting a potential benefit for combined anti-TGF-β therapy.
Synapse has enriched 10 related papers. Consider them for comparative context: